Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation

BACKGROUND: While major advances have been made in improving the quality of life and survival of children with most forms of medulloblastoma (MB), those with MYC-driven tumors (Grp3-MB) still suffer significant morbidity and mortality. There is an urgent need to explore multimodal therapeutic regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Marquardt, Viktoria, Theruvath, Johanna, Pauck, David, Picard, Daniel, Qin, Nan, Blümel, Lena, Maue, Mara, Bartl, Jasmin, Ahmadov, Ulvi, Langini, Maike, Meyer, Frauke-Dorothee, Cole, Allison, Cruz-Cruz, Joselyn, Graef, Claus M, Wölfl, Matthias, Milde, Till, Witt, Olaf, Erdreich-Epstein, Anat, Leprivier, Gabriel, Kahlert, Ulf, Stefanski, Anja, Stühler, Kai, Keir, Stephen T, Bigner, Darell D, Hauer, Julia, Beez, Thomas, Knobbe-Thomsen, Christiane B, Fischer, Ute, Felsberg, Jörg, Hansen, Finn K, Vibhakar, Rajeev, Venkatraman, Sujatha, Cheshier, Samuel H, Reifenberger, Guido, Borkhardt, Arndt, Kurz, Thomas, Remke, Marc, Mitra, Siddhartha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843227/
https://www.ncbi.nlm.nih.gov/pubmed/36639156
http://dx.doi.org/10.1136/jitc-2022-005871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843227/
https://www.ncbi.nlm.nih.gov/pubmed/36639156
http://dx.doi.org/10.1136/jitc-2022-005871

Ejemplares similares